N-(4-(2-methylmorpholino)pyridin-3-yl)-2-(4-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-8-carboxamide

ID: ALA5286737

Chembl Id: CHEMBL5286737

Max Phase: Preclinical

Molecular Formula: C24H21F3N6O2

Molecular Weight: 482.47

Names and Identifiers

Canonical SMILES:  CC1CN(c2ccncc2NC(=O)c2ccnn3cc(-c4ccc(C(F)(F)F)cc4)nc23)CCO1

Standard InChI:  InChI=1S/C24H21F3N6O2/c1-15-13-32(10-11-35-15)21-7-8-28-12-19(21)31-23(34)18-6-9-29-33-14-20(30-22(18)33)16-2-4-17(5-3-16)24(25,26)27/h2-9,12,14-15H,10-11,13H2,1H3,(H,31,34)

Standard InChI Key:  WWEHEGICBBJKLI-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA5286737

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 482.47

Molecular Weight (Monoisotopic): 482.1678

AlogP: 4.29

#Rotatable Bonds: 4

Polar Surface Area: 84.65

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 7.98

CX LogP: 3.74

CX LogD: 3.21

Aromatic Rings: 4

Heavy Atoms: 35

QED Weighted: 0.47

Np Likeness Score: -1.92

References

1. Hartz RA, Ahuja VT, Sivaprakasam P, Xiao H, Krause CM, Clarke WJ, Kish K, Lewis H, Szapiel N, Ravirala R, Mutalik S, Nakmode D, Shah D, Burton CR, Macor JE, Dubowchik GM..  (2023)  Design, Structure-Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-b]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors.,  66  (6): [PMID:36950863] [10.1021/acs.jmedchem.3c00133]

Source

Source(1):

• Scientific Literature